Novel therapies tested in SLE comprise anti-cytokines antibodies (for example, anti-interleukin(IL)-6), anti-B cell therapies targeting either B cell surface antigens (anti-CD20, anti-CD22) or B cell survival factors (for example, anti-BLyS/APRIL monoclonal antibodies), as well as drugs intervening in B-T cell co-stimulation (CTLA4-Ig) [1-12]. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.